{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T10:26:41Z","timestamp":1790850401529,"version":"4.1.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s00228-023-03474-8","type":"journal-article","created":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T05:57:57Z","timestamp":1680501477000},"page":"609-616","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Teplizumab: type 1 diabetes mellitus preventable?"],"prefix":"10.1007","volume":"79","author":[{"given":"Saurav","family":"Misra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay Kumar","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,1]]},"reference":[{"issue":"4","key":"3474_CR1","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1177\/1742395318799844","volume":"16","author":"N Saxby","year":"2020","unstructured":"Saxby N, Beggs S, Kariyawasam N, Battersby M, Lawn S (2020) Do guidelines provide evidence-based guidance to health professionals on promoting developmentally appropriate chronic condition self-management in children? A Syst Rev Chronic Illn 16(4):239\u2013252","journal-title":"A systematic review Chronic Illn"},{"issue":"16","key":"3474_CR2","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1017\/S0950268818002455","volume":"146","author":"Y Yue","year":"2018","unstructured":"Yue Y, Tang Y, Tang J, Shi J, Zhu T, Huang J et al (2018) Maternal infection during pregnancy and type 1 diabetes mellitus in offspring: a systematic review and meta-analysis. Epidemiol Infect 146(16):2131\u20132138","journal-title":"Epidemiol Infect"},{"key":"3474_CR3","unstructured":"Lucier J, Weinstock RS (2022) Diabetes Mellitus Type 1. [Updated 2022 May 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK507713\/"},{"issue":"6865","key":"3474_CR4","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1038\/414782a","volume":"414","author":"P Zimmet","year":"2001","unstructured":"Zimmet P, Alberti KG, Shaw J (2001) Global and societal implications of the diabetes epidemic. Nature 414(6865):782\u2013787","journal-title":"Nature"},{"issue":"4","key":"3474_CR5","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/nrendo.2011.183","volume":"8","author":"L Chen","year":"2011","unstructured":"Chen L, Magliano DJ, Zimmet PZ (2011) The worldwide epidemiology of type 2 diabetes mellitus\u2013present and future perspectives. Nat Rev Endocrinol 8(4):228\u2013236","journal-title":"Nat Rev Endocrinol"},{"key":"3474_CR6","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.2337\/db18-0065","volume":"67","author":"CJ Greenbaum","year":"2018","unstructured":"Greenbaum CJ, Speake C, Krischer J, Buckner J, Gottlieb PA, Schatz DA et al (2018) Strength in numbers: opportunities for enhancing the development of effective treatments for type 1 diabetes-the TrialNet experience. Diabetes 67:1216\u20131225","journal-title":"Diabetes"},{"issue":"9911","key":"3474_CR7","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S0140-6736(13)60591-7","volume":"383","author":"MA Atkinson","year":"2014","unstructured":"Atkinson MA, Eisenbarth GS, Michels AW (2014) Type 1 diabetes. Lancet 383(9911):69\u201382","journal-title":"Lancet"},{"issue":"8","key":"3474_CR8","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1007\/s00125-012-2571-8","volume":"55","author":"CC Patterson","year":"2012","unstructured":"Patterson CC, Gy\u00fcr\u00fcs E, Rosenbauer J, Cinek O, Neu A, Schober E et al (2012) Trends in childhood type 1 diabetes incidence in Europe during 1989\u20132008: evidence of non-uniformity over time in rates of increase. Diabetologia 55(8):2142\u20132147","journal-title":"Diabetologia"},{"key":"3474_CR9","unstructured":"Indian Council of Medical Research (ICMR) [home page in Internet] ICMR Guidelines for management of type 1 diabetes. [Last Cited on 27th January 2023]. Available from: https:\/\/main.icmr.nic.in\/sites\/default\/files\/upload_documents\/ICMR_Guidelines_for_Management_of_Type_1_Diabetes.pdf"},{"key":"3474_CR10","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/j.0105-2896.2005.00248.x","volume":"204","author":"R Gianani","year":"2005","unstructured":"Gianani R, Eisenbarth GS (2005) The stages of type 1A diabetes: 2005. Immunol Rev 204:232\u2013249","journal-title":"Immunol Rev"},{"issue":"5","key":"3474_CR11","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.2337\/diacare.28.5.1068","volume":"28","author":"JS Skyler","year":"2005","unstructured":"Skyler JS, Krischer JP, Wolfsdorf J, Cowie C, Palmer JP, Greenbaum C et al (2005) Effects of oral insulin in relatives of patients with type 1 diabetes: the diabetes prevention trial\u2013type 1. Diabetes Care 28(5):1068\u20131076","journal-title":"Diabetes Care"},{"key":"3474_CR12","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1038\/sj.clpt.6100179","volume":"81","author":"JS Skyler","year":"2007","unstructured":"Skyler JS (2007) Prediction and prevention of type 1 diabetes: progress, problems, and prospects. Clin Pharmacol Ther 81:768\u2013771","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"3474_CR13","doi-asserted-by":"publisher","first-page":"66","DOI":"10.2337\/diacare.15.1.66","volume":"15","author":"S Martin","year":"1992","unstructured":"Martin S, Pawlowski B, Greulich B, Ziegler AG, Mandrup-Poulsen T, Mahon J (1992) Natural course of remission in IDDM during 1st yr after diagnosis. Diabetes Care 15(1):66\u201374","journal-title":"Diabetes Care"},{"issue":"11","key":"3474_CR14","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.tibtech.2006.08.007","volume":"24","author":"L Pasquali","year":"2006","unstructured":"Pasquali L, Fan Y, Trucco M, Ringquist S (2006) Rehabilitation of adaptive immunity and regeneration of beta cells. Trends Biotechnol 24(11):516\u2013522","journal-title":"Trends Biotechnol"},{"issue":"3","key":"3474_CR15","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1517\/14712591003598843","volume":"10","author":"UB Masharani","year":"2010","unstructured":"Masharani UB, Becker J (2010) Teplizumab therapy for type 1 diabetes. Expert Opin Biol Ther 10(3):459\u2013465","journal-title":"Expert Opin Biol Ther"},{"key":"3474_CR16","unstructured":"Subramanian S, Baidal D (2021) The management of type 1 diabetes. In: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK279114\/23"},{"issue":"6","key":"3474_CR17","first-page":"271","volume":"2","author":"GS Eisenbarth","year":"1985","unstructured":"Eisenbarth GS, Srikanta S, Jackson R, Rabinowe S, Dolinar R, Aoki T et al (1985) Anti-thymocyte globulin and prednisone immunotherapy of recent onset type 1 diabetes mellitus. Diabetes Res 2(6):271\u2013276","journal-title":"Diabetes Res"},{"issue":"10","key":"3474_CR18","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.2337\/diab.39.10.1264","volume":"39","author":"PF Bougn\u00e8res","year":"1990","unstructured":"Bougn\u00e8res PF, Landais P, Boisson C, Carel JC, Frament N, Boitard C et al (1990) Limited duration of remission of insulin dependency in children with recent overt type I diabetes treated with low-dose cyclosporin. Diabetes 39(10):1264\u20131272","journal-title":"Diabetes"},{"key":"3474_CR19","doi-asserted-by":"crossref","unstructured":"Parving HH, Tarnow L, Nielsen FS, Rossing P, Mandrup-Poulsen T, Osterby R et al (1999) Cyclosporine nephrotoxicity in type 1 diabetic patients. A 7-year follow-up study. Diabetes Care 22(3):478\u201383","DOI":"10.2337\/diacare.22.3.478"},{"issue":"10","key":"3474_CR20","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJM198809083191002","volume":"319","author":"J Silverstein","year":"1988","unstructured":"Silverstein J, Maclaren N, Riley W, Spillar R, Radjenovic D, Johnson S (1988) Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus. N Engl J Med 319(10):599\u2013604","journal-title":"N Engl J Med"},{"issue":"3","key":"3474_CR21","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/nrendo.2009.275","volume":"6","author":"L Chatenoud","year":"2010","unstructured":"Chatenoud L (2010) Immune therapy for type 1 diabetes mellitus-what is unique about anti-CD3 antibodies? Nat Rev Endocrinol 6(3):149\u2013157","journal-title":"Nature reviews Endocrinol"},{"key":"3474_CR22","doi-asserted-by":"crossref","unstructured":"Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, Goland R et al (2009) Type 1 Diabetes TrialNet Anti-CD20 Study Group. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 361(22):2143\u201352","DOI":"10.1056\/NEJMoa0904452"},{"key":"3474_CR23","doi-asserted-by":"crossref","unstructured":"Orban T, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R et al (2011) Type 1 Diabetes TrialNet Abatacept Study Group. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 378(9789):412\u20139","DOI":"10.1016\/S0140-6736(11)60886-6"},{"key":"3474_CR24","doi-asserted-by":"crossref","unstructured":"Rigby MR, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE et al (2013) T1DAL Study Team. Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol 1(4):284\u201394","DOI":"10.1016\/S2213-8587(13)70111-6"},{"key":"3474_CR25","doi-asserted-by":"crossref","unstructured":"Pescovitz MD, Greenbaum CJ, Bundy B, Becker DJ, Gitelman SE, Goland R et al (2014) Type 1 Diabetes TrialNet Anti-CD20 Study Group. B-lymphocyte depletion with rituximab and \u03b2-cell function: two-year results. Diabetes Care 37(2):453\u20139","DOI":"10.2337\/dc13-0626"},{"issue":"9881","key":"3474_CR26","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1016\/S0140-6736(13)60023-9","volume":"381","author":"A Moran","year":"2013","unstructured":"Moran A, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R et al (2013) Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet 381(9881):1905\u20131915","journal-title":"Lancet"},{"issue":"7","key":"3474_CR27","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1007\/s00125-009-1371-2","volume":"52","author":"CD Agardh","year":"2009","unstructured":"Agardh CD, Lynch KF, Palm\u00e9r M, Link K, Lernmark A (2009) GAD65 vaccination: 5 years of follow-up in a randomised dose-escalating study in adult-onset autoimmune diabetes. Diabetologia 52(7):1363\u20131368","journal-title":"Diabetologia"},{"issue":"7","key":"3474_CR28","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.2337\/dc09-0054","volume":"32","author":"L Mastrandrea","year":"2009","unstructured":"Mastrandrea L, Yu J, Behrens T, Buchlis J, Albini C, Fourtner S et al (2009) Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study. Diabetes Care 32(7):1244\u20131249","journal-title":"Diabetes Care"},{"key":"3474_CR29","doi-asserted-by":"crossref","unstructured":"Roep BO, Solvason N, Gottlieb PA, Abreu JRF, Harrison LC, Eisenbarth GS et al (2013) BHT-3021 Investigators; Steinman L. Plasmid-encoded proinsulin preserves C-peptide while specifically reducing proinsulin-specific CD8+ T cells in type 1 diabetes. Sci Transl Med 5(191):191ra82","DOI":"10.1126\/scitranslmed.3006103"},{"issue":"6","key":"3474_CR30","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.4049\/jimmunol.158.6.2947","volume":"158","author":"L Chatenoud","year":"1997","unstructured":"Chatenoud L, Primo J, Bach JF (1997) CD3 antibody-induced dominant self-tolerance in overtly diabetic NOD mice. J Immunol 158(6):2947\u20132954","journal-title":"J Immunol"},{"issue":"5","key":"3474_CR31","first-page":"2017","volume":"31","author":"A Nadeem","year":"2018","unstructured":"Nadeem A, Ashraf MR, Javed M, Hussain T, Tariq MS, Babar ME (2018) Review - microRNAs: a new paradigm towards mechanistic insight of diseases. Pak J Pharm Sci 31(5):2017\u20132026","journal-title":"Pak J Pharm Sci"},{"key":"3474_CR32","unstructured":"Drugbank [Home page in Internet] Teclizumab. [Last cited on 27th January 2023] Available from: https:\/\/go.drugbank.com\/drugs\/DB06273"},{"issue":"6","key":"3474_CR33","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1056\/NEJM198108063050603","volume":"305","author":"AB Cosimi","year":"1981","unstructured":"Cosimi AB, Colvin RB, Burton RC, Rubin RH, Goldstein G, Kung PC et al (1981) Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts. N Engl J Med 305(6):308\u2013314","journal-title":"N Engl J Med"},{"key":"3474_CR34","unstructured":"Hooks MA, Wade CS, Millikan WJ Jr (1991) Muromonab CD-3: a review of its pharmacology, pharmacokinetics, and 37. clinical use in transplantation. Pharmacotherapy 11(1):26\u201337"},{"issue":"3","key":"3474_CR35","doi-asserted-by":"publisher","first-page":"830","DOI":"10.4049\/jimmunol.137.3.830","volume":"137","author":"L Chatenoud","year":"1986","unstructured":"Chatenoud L, Baudrihaye MF, Chkoff N, Kreis H, Goldstein G, Bach JF (1986) Restriction of the human in vivo immune response against the mouse monoclonal antibody OKT3. J Immunol 137(3):830\u2013838","journal-title":"J Immunol"},{"key":"3474_CR36","doi-asserted-by":"crossref","unstructured":"Chatenoud L, Ferran C, Legendre C, Thouard I, Merite S, Reuter A et al (1990) In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids. Transplantation 49(4):697\u2013702","DOI":"10.1097\/00007890-199004000-00009"},{"issue":"5","key":"3474_CR37","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1002\/eji.1830160503","volume":"16","author":"KG Smith","year":"1986","unstructured":"Smith KG, Austyn JM, Hariri G, Beverley PC, Morris PJ (1986) T cell activation by anti-T3 antibodies: comparison of IgG1 and IgG2b switch variants and direct evidence for accessory function of macrophage Fc receptors. Eur J Immunol 16(5):478\u2013486","journal-title":"Eur J Immunol"},{"key":"3474_CR38","doi-asserted-by":"crossref","unstructured":"Parren PW, Warmerdam PA, Boeije LC, Capel PJ, van de Winkel JG, Aarden LA (1992) Characterization of IgG FcR-mediated proliferation of human T cells induced by mouse and human anti-CD3 monoclonal antibodies. Identification of a functional polymorphism to human IgG2 anti-CD3. J Immunol 148(3):695\u2013701","DOI":"10.4049\/jimmunol.148.3.695"},{"issue":"2","key":"3474_CR39","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1097\/00007890-199901270-00011","volume":"67","author":"H Vallhonrat","year":"1999","unstructured":"Vallhonrat H, Williams WW, Cosimi AB, Tolkoff-Rubin N, Ginns LC, Wain JC et al (1999) In vivo generation of C4d, Bb, iC3b, and SC5b-9 after OKT3 administration in kidney and lung transplant recipients. Transplantation 67(2):253\u2013258","journal-title":"Transplantation"},{"issue":"6","key":"3474_CR40","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1097\/00007890-199006000-00018","volume":"49","author":"R Hirsch","year":"1990","unstructured":"Hirsch R, Bluestone JA, DeNenno L, Gress RE (1990) Anti-CD3 F(ab\u2019)2 fragments are immunosuppressive in vivo without evoking either the strong humoral response or morbidity associated with whole mAb. Transplantation 49(6):1117\u20131123","journal-title":"Transplantation"},{"issue":"4","key":"3474_CR41","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1097\/00007890-199908270-00020","volume":"68","author":"MS Cole","year":"1999","unstructured":"Cole MS, Stellrecht KE, Shi JD, Homola M, Hsu DH, Anasetti C et al (1999) HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro. Transplantation 68(4):563\u2013571","journal-title":"Transplantation"},{"issue":"1","key":"3474_CR42","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1006\/cimm.2000.1617","volume":"200","author":"D Xu","year":"2000","unstructured":"Xu D, Alegre ML, Varga SS, Rothermel AL, Collins AM, Pulito VL et al (2000) In vitro characterization of five humanized OKT3 effector function variant antibodies. Cell Immunol 200(1):16\u201326","journal-title":"Cell Immunol"},{"issue":"3","key":"3474_CR43","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1517\/14712598.2014.881797","volume":"14","author":"NK Vudattu","year":"2014","unstructured":"Vudattu NK, Herold KC (2014) Treatment of new onset type 1 diabetes with teplizumab: successes and pitfalls in development. Expert Opin Biol Ther 14(3):377\u2013385","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"3474_CR44","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.clim.2013.05.001","volume":"149","author":"AG Daifotis","year":"2013","unstructured":"Daifotis AG, Koenig S, Chatenoud L, Herold KC (2013) Anti-CD3 clinical trials in type 1 diabetes mellitus. Clin Immunol 149(3):268\u2013278","journal-title":"Clin Immunol"},{"key":"3474_CR45","doi-asserted-by":"crossref","unstructured":"Hagopian W, Ferry RJ Jr, Sherry N, Carlin D, Bonvini E, Johnson S et al (2013) Prot\u00e9g\u00e9 Trial Investigators. Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Prot\u00e9g\u00e9 trial. Diabetes 62(11):3901\u20138","DOI":"10.2337\/db13-0236"},{"key":"3474_CR46","unstructured":"U.S Food and Drug Administration [Home page in Internet] FDA approved drug products: TZIELD (teplizumab-mzwv) injection for intravenous use. [Last Cited on 27th January 2023] Available from:\u00a0https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-drug-can-delay-onset-type-1-diabetes"},{"key":"3474_CR47","doi-asserted-by":"crossref","unstructured":"Sims EK, Bundy BN, Stier K, Serti E, Lim N, Long SA et al (2021) Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. Sci Transl Med 13(583):eabc8980","DOI":"10.1126\/scitranslmed.abc8980"},{"key":"3474_CR48","doi-asserted-by":"crossref","unstructured":"Smigoc Schweiger D (2022) Recent advances in immune-based therapies for type 1 diabetes. Horm Res Paediatr","DOI":"10.1159\/000524866"},{"issue":"10205","key":"3474_CR49","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/S0140-6736(19)32127-0","volume":"394","author":"CM Dayan","year":"2019","unstructured":"Dayan CM, Korah M, Tatovic D, Bundy BN, Herold KC (2019) Changing the landscape for type 1 diabetes: the first step to prevention. Lancet 394(10205):1286\u20131296","journal-title":"Lancet"},{"issue":"1","key":"3474_CR50","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/biomedicines9010042","volume":"9","author":"JL Felton","year":"2021","unstructured":"Felton JL, Conway H, Bonami RH (2021) B Quiet: autoantigen-specific strategies to silence raucous B lymphocytes and halt cross-talk with t cells in type 1 diabetes. Biomedicines 9(1):42","journal-title":"Biomedicines"},{"issue":"40","key":"3474_CR51","doi-asserted-by":"publisher","first-page":"4107","DOI":"10.1021\/acs.biochem.9b00707","volume":"58","author":"J Gaglia","year":"2019","unstructured":"Gaglia J, Kissler S (2019) Anti-CD3 antibody for the prevention of type 1 diabetes: a story of perseverance. Biochemistry 58(40):4107\u20134111","journal-title":"Biochemistry"},{"issue":"1","key":"3474_CR52","doi-asserted-by":"publisher","first-page":"1860476","DOI":"10.1080\/19420862.2020.1860476","volume":"13","author":"H Kaplon","year":"2021","unstructured":"Kaplon H, Reichert JM (2021) Antibodies to watch in 2021. MAbs 13(1):1860476","journal-title":"MAbs"},{"issue":"7","key":"3474_CR53","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1902226","volume":"381","author":"KC Herold","year":"2019","unstructured":"Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ et al (2019) An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med 381(7):603\u2013613","journal-title":"N Engl J Med"},{"issue":"4","key":"3474_CR54","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1097\/MED.0000000000000488","volume":"26","author":"PS Linsley","year":"2019","unstructured":"Linsley PS, Long SA (2019) Enforcing the checkpoints: harnessing T-cell exhaustion for therapy of T1D. Curr Opin Endocrinol Diabetes Obes 26(4):213\u2013218","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"1","key":"3474_CR55","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1002\/eji.201545708","volume":"46","author":"JE Tooley","year":"2016","unstructured":"Tooley JE, Vudattu N, Choi J, Cotsapas C, Devine L, Raddassi K et al (2016) Changes in T-cell subsets identify responders to FcR-nonbinding anti-CD3 mAb (teplizumab) in patients with type 1 diabetes. Eur J Immunol 46(1):230\u2013241","journal-title":"Eur J Immunol"},{"issue":"6","key":"3474_CR56","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.4049\/jimmunol.158.6.2947","volume":"158","author":"L Chatenoud","year":"1997","unstructured":"Chatenoud L, Primo J, Bach JF (1997) CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol 158(6):2947\u20132954","journal-title":"J Immunol"},{"issue":"15","key":"3474_CR57","doi-asserted-by":"publisher","first-page":"6335","DOI":"10.1073\/pnas.0701171104","volume":"104","author":"S You","year":"2007","unstructured":"You S, Leforban B, Garcia C, Bach JF, Bluestone JA, Chatenoud L (2007) Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment. Proc Natl Acad Sci U S A 104(15):6335\u20136340","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3474_CR58","doi-asserted-by":"crossref","unstructured":"You S, Slehoffer G, Barriot S, Bach JF, Chatenoud L (2004) Unique role of CD4+CD62L+ regulatory T cells in the control of autoimmune diabetes in T cell receptor transgenic mice. Proc Natl Acad Sci USA 101(Suppl 2):14580\u20135","DOI":"10.1073\/pnas.0404870101"},{"issue":"9","key":"3474_CR59","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1038\/nm924","volume":"9","author":"M Belghith","year":"2003","unstructured":"Belghith M, Bluestone JA, Barriot S, M\u00e9gret J, Bach JF, Chatenoud L (2003) TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med 9(9):1202\u20131208","journal-title":"Nat Med"},{"issue":"4","key":"3474_CR60","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.4049\/jimmunol.1100713","volume":"187","author":"C Penaranda","year":"2011","unstructured":"Penaranda C, Tang Q, Bluestone JA (2011) Anti-CD3 therapy promotes tolerance by selectively depleting pathogenic cells while preserving regulatory T cells. J Immunol 187(4):2015\u20132022","journal-title":"J Immunol"},{"issue":"7357","key":"3474_CR61","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/nature10228","volume":"475","author":"E Esplugues","year":"2011","unstructured":"Esplugues E, Huber S, Gagliani N, Hauser AE, Town T, Wan YY et al (2011) Control of TH17 cells occurs in the small intestine. Nature 475(7357):514\u2013518","journal-title":"Nature"},{"key":"3474_CR62","doi-asserted-by":"crossref","unstructured":"Waldron-Lynch F, Henegariu O, Deng S, Preston-Hurlburt P, Tooley J, Flavell R et al (2012) Teplizumab induces human gut-tropic regulatory cells in humanized mice and patients. Sci Transl Med 4(118):118ra12","DOI":"10.1126\/scitranslmed.3003401"},{"issue":"10","key":"3474_CR63","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.2174\/1871530320999201209222921","volume":"21","author":"AZ Nourelden","year":"2021","unstructured":"Nourelden AZ, Elshanbary AA, El-Sherif L, Benmelouka AY, Rohim HI, Helmy SK et al (2021) Safety and efficacy of teplizumab for treatment of type one diabetes mellitus: a systematic review and meta-analysis. Endocr Metab Immune Disord Drug Targets 21(10):1895\u20131904","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"3474_CR64","doi-asserted-by":"crossref","unstructured":"Herold KC, Gitelman SE, Ehlers MR, Gottlieb PA, Greenbaum CJ, Hagopian W, Boyle KD, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, McNamara J, Bluestone JA (2013) AbATE Study Team. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes 62(11):3766\u201374","DOI":"10.2337\/db13-0345"},{"issue":"10","key":"3474_CR65","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1345\/aph.1R065","volume":"46","author":"JW Skelley","year":"2012","unstructured":"Skelley JW, Elmore LK, Kyle JA (2012) Teplizumab for treatment of type 1 diabetes mellitus. Ann Pharmacother 46(10):1405\u20131412","journal-title":"Ann Pharmacother"},{"issue":"12","key":"3474_CR66","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1007\/s40273-020-00962-y","volume":"38","author":"S Mital","year":"2020","unstructured":"Mital S, Nguyen HV (2020) Cost effectiveness of teplizumab for prevention of type 1 diabetes among different target patient groups. Pharmacoeconomics 38(12):1359\u20131372","journal-title":"Pharmacoeconomics"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-023-03474-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-023-03474-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-023-03474-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T09:09:42Z","timestamp":1681722582000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-023-03474-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,1]]},"references-count":66,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["3474"],"URL":"https:\/\/doi.org\/10.1007\/s00228-023-03474-8","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,1]]},"assertion":[{"value":"14 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}